Actinium-225 PSMA Therapy (Ac-225 PSMA) is one of the most promising new treatments in the field of nuclear medicine for advanced prostate cancer. It uses a powerful alpha-emitting radioisotope to target and destroy prostate cancer cells at the molecular level. At Neolife Medical Center, we are proud to offer this cutting-edge treatment as part of our comprehensive, personalized cancer care programs for international patients.
Actinium-225 PSMA therapy is primarily intended for patients with metastatic castration-resistant prostate cancer (mCRPC)—a stage of prostate cancer that has spread to other parts of the body and no longer responds to hormone therapy.
You may be a good candidate for Ac-225 PSMA treatment if:
At Neolife Medical Center, we are at the forefront of targeted radionuclide therapies, offering Actinium-225 PSMA to eligible patients in a safe, supportive, and internationally accredited environment.
At Neolife, our goal is to combine cutting-edge treatment with personalized care, making sure every patient feels supported throughout their medical journey.
Getting started with Ac-225 PSMA therapy at Neolife Medical Center is simple and fully supported by our International Patient Department. Here’s how you can begin:
Access One of the Most Powerful Prostate Cancer Therapies Available Today
Contact Neolife Medical Center now to learn more about Actinium-225 PSMA Treatment and receive your personalized care plan.